Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.39 |
| ▸ | CTSC | P53634 | 5/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7193468 | 0.87 | PTPN1 (0.45) | NR1H2NR1H3CTSCPTK2 | |
| SCHEMBL7592239 | 0.78 | PTPN1 (0.50) | — | |
| SCHEMBL5404860 | 0.77 | PTPN1 (0.51) | NR1H2NR1H3 | |
| SCHEMBL7188776 | 0.77 | PTPN1 (0.49) | — | |
| SCHEMBL5413494 | 0.75 | PTPN1 (0.40) | NR1H2NR1H3RXRA | |
| SCHEMBL14627010 | 0.73 | NR1H2 (0.38) | NR1H2NR1H3CTSKRXRA | |
| SCHEMBL7577988 | 0.72 | CETP (0.40) | — | |
| SCHEMBL7198006 | 0.71 | PTPN1 (0.42) | — | |
| SCHEMBL7193789 | 0.69 | MCHR1 (0.32) | — | |
| SCHEMBL7595787 | 0.68 | GFER (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163932-B2 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA & CO. (CA) | 2007-01-16 | — | — | US | disclosed |
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA LTD. (CA) | 2004-09-09 | — | — | US | disclosed |
| WO-2002102813-A1 | ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS FOR TREATMENT OF DIABETES | MERCK FROSST CANADA & CO. (CA) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | PTPRF, PTPRO, PTP4A1 | NR1H2 2460/4885NR1H3 2618/4885CTSC 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.